Welcome to our dedicated page for Nucana news (Ticker: NCNA), a resource for investors and traders seeking the latest updates and insights on Nucana stock.
NuCana plc develops cancer medicines based on its proprietary ProTide technology, with news centered on the ADR-listed clinical-stage biopharmaceutical company’s oncology pipeline and corporate updates. Recurring releases describe NUC-7738, a novel anti-cancer agent being studied as a monotherapy in advanced solid tumors and with pembrolizumab in melanoma, and NUC-3373, a 5-fluorouracil-derived new chemical entity being studied with pembrolizumab and docetaxel in advanced solid tumors and lung cancer.
Company updates also cover clinical and translational data presentations, patent protection for NUC-7738, quarterly and annual financial results, cash runway commentary, executive and board changes, and Nasdaq continued-listing matters for NuCana’s American depositary shares.
NuCana plc (NASDAQ: NCNA) announced it has regained compliance with the Nasdaq Minimum Bid Price Requirement after a period of non-compliance. The company received a notification confirming that its American Depositary Shares (ADSs) maintained a closing bid price of $1.00 or more for 10 consecutive business days from July 13 to July 26, 2022. This follows previous notification on June 3, 2022, regarding falling below the minimum required price. NuCana focuses on improving cancer treatment outcomes using its innovative ProTide technology, with ongoing clinical trials for its product candidates.
NuCana (NASDAQ: NCNA) announced a significant legal victory on July 7, 2022, when the Regional Court of Dusseldorf ruled that Gilead Sciences violated NuCana’s European Patent 2955190 regarding their products Sovaldi®, Harvoni®, Vosevi®, and Epclusa® in Germany. The court's decision comes after Gilead’s failed attempts to invalidate the patent. Following the judgment, Gilead may appeal, and ongoing UK litigation regarding the patent remains unresolved. NuCana continues to develop innovative cancer treatments utilizing its proprietary ProTide technology.
NuCana plc (NASDAQ: NCNA) announced promising non-clinical results for NUC-7738, a treatment for Acute Myeloid Leukemia (AML), showcased at the EHA 2022 Congress. NUC-7738 demonstrated effectiveness in reducing AML cell proliferation and overcoming resistance to standard chemotherapy. The drug targets β-catenin signaling, indicating broad therapeutic potential. With a favorable safety profile observed in previous studies, NuCana is evaluating NUC-7738 for possible advancement in hematologic malignancies.
NuCana plc (NASDAQ: NCNA) received a Notification Letter from Nasdaq indicating non-compliance with Listing Rule 5450(a)(1) due to a closing bid price of less than $1.00 per share for 30 consecutive business days.
The company has a 180-day grace period, until November 23, 2022, to regain compliance by achieving a bid price of $1.00 or higher for at least ten consecutive business days. The company's ADSs will continue to trade on Nasdaq during this period, and options to regain compliance are being evaluated.
NuCana plc (NASDAQ: NCNA) announced financial results for Q1 2022, reporting a net loss of £8.4 million, an improvement from £9.8 million in Q1 2021. Cash and equivalents stood at £52.6 million as of March 31, 2022. The company initiated a randomized Phase 2 study of NUC-3373 for colorectal cancer and a Phase 1b/2 study in combination with PD-1 inhibitors. The first patients have been enrolled in the Phase 2 study of NUC-7738. NuCana is well-capitalized with a projected cash runway into 2025, indicating potential for significant clinical milestones.
NuCana plc (NASDAQ: NCNA) announced that Don Munoz, Chief Financial Officer, will hold one-on-one meetings at the Jefferies Healthcare Conference from June 8-10, 2022, in New York, NY. The company focuses on enhancing cancer treatment outcomes through its proprietary ProTide technology, which aims to develop safer and more effective medicines. NuCana’s key product candidates include NUC-3373, in a Phase 1b/2 study for metastatic colorectal cancer, and NUC-7738, in a Phase 1/2 study for advanced solid tumors.
NuCana (NASDAQ: NCNA) reported Q4 and FY 2021 results, revealing a net loss of £40.5 million for the year, higher than the previous year's £30.7 million. As of December 31, 2021, cash reserves were £60.3 million, down from £71 million in Q3 2021. The company plans to launch a Phase 2 study for NUC-3373 in colorectal cancer, aiming for a simplified subsequent Phase 3 study. Additionally, NUC-7738 is advancing into Phase 2, following promising Phase 1 results. NuCana expects a cash runway into 2025, supporting ongoing and upcoming clinical trials.
NuCana plc (NASDAQ: NCNA) announced promising data on its drug NUC-3373 aimed at improving cancer treatment. Presented at the AACR Annual Meeting, the research indicates that NUC-3373 enhances immune response and cell death in colorectal cancer cell lines when combined with nivolumab. Furthermore, NUC-3373 is shown to be more effective than 5-FU, producing higher levels of active metabolites and avoiding its associated toxicities. The company is advancing NUC-3373 into more clinical studies, reinforcing its strategy for treating colorectal cancer.
NuCana plc (NASDAQ: NCNA) has announced the discontinuation of the NuTide:121 study following a futility analysis by its Independent Data Monitoring Committee. Despite a higher objective response rate for Acelarin plus cisplatin, there was no observed overall survival benefit compared to standard treatments. The company remains committed to cancer therapies and is progressing with other candidates, NUC-3373 and NUC-7738, with multiple data readouts expected throughout 2022. The firm emphasizes its robust financial position to support ongoing clinical trials.
NuCana plc (Nasdaq: NCNA) announces participation in two virtual investor conferences. The first is Cowen’s 42nd Annual Healthcare Conference from March 7-9, 2022. The second event is Oppenheimer's 32nd Annual Healthcare Conference on March 16, 2022, at 8:00 AM ET, which will be webcasted live. NuCana focuses on improving cancer treatment through its ProTide technology, with three ProTides in clinical development: Acelarin, NUC-3373, and NUC-7738. Acelarin is in Phase 3 for advanced biliary tract cancer, while NUC-3373 and NUC-7738 are in earlier studies for colorectal and solid tumors.